Lineage Cell Therapeutics
LCTX
127 hedge funds and large institutions have $54M invested in Lineage Cell Therapeutics in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 16 reducing their positions, and 13 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 16
118% more capital inflows, than outflows
Capital inflows: $15.4M | Capital outflows: $7.06M
115% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 13
10% more funds holding
Funds holding: 115 → 127 (+12)
1.47% less ownership
Funds ownership: 50.18% → 48.71% (-1.5%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$5.31M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.9M |
| 3 |
Renaissance Technologies
New York
|
+$1.53M |
| 4 |
DAFNA Capital Management
Los Angeles,
California
|
+$852K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$759K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logos Global Management
San Francisco,
California
|
-$4.53M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$980K |
| 3 |
MAI Capital Management
Independence,
Ohio
|
-$747K |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
-$249K |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$195K |
LCTX Hedge Fund Activity: Q4 2024 in Review
127 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2024, worth a combined $54M — down 37% from $85.8M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new LCTX positions and 13 closed out — a net gain of 15 holders — while 39 added to existing stakes and 16 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.31M. The largest seller was Logos Global Management, exiting entirely with an estimated $4.53M sold.
- 127 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2024, up from 115 in Q3 2024.
- Funds reported $54M of Lineage Cell Therapeutics stock for Q4 2024, down 37% quarter-over-quarter.
- 28 funds opened new Lineage Cell Therapeutics positions in Q4 2024 and 13 closed out, a net change of +15 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2024 was Perceptive Advisors, an estimated $5.31M added.
- The largest Lineage Cell Therapeutics seller in Q4 2024 was Logos Global Management, an estimated $4.53M sold.
Based on aggregated 13F filings for Q4 2024.